Skip to main
  1. Stocks
  2. Iovance Biotherapeutics
  3. Forecast
IOVA

Iovance Biotherapeutics (IOVA) Stock Forecast & Price Target

Iovance Biotherapeutics (IOVA) Analyst Ratings

Based on 10 analyst ratings
Buy
Strong Buy 40%
Buy 40%
Hold 20%
Sell 0%
Strong Sell 0%

Bulls say

Iovance Biotherapeutics is attractive because its lead TIL therapy is showing clinically differentiated durability and depth of response, with 3Q26 revenue of $122MM, melanoma ORR of 62.5% and CR rate of 29.2%, and NSCLC responses still ongoing in 9 of 17 responders. It also has a meaningful commercial tailwind, as 3Q26 results beat estimates, cash and equivalents were $382.3MM, and the company raised FY26 revenue guidance to $410MM-$420MM on strong AMTAGVI and Proleukin demand. The outlook is further supported by an expanding authorized treatment center network above 100 sites, faster manufacturing turnaround near 30 days, and multiple upcoming catalysts in ESMO'26, 4Q26, and 2027 that could broaden adoption across solid tumors.

Bears say

Iovance Biotherapeutics is viewed negatively because lifileucel’s NSCLC dataset showed only stable efficacy as it expanded, with ORR at 24.6% (17/69) versus 25.6% previously, while durability looks weaker as an estimated 4 of 13 responses ended within six months and the company withheld updated median DOR, PFS, and OS. The slower durability profile, including an observed median DOR of about 10 months in 2026 versus 12 months in 2025 and a greater frequency of early progression, raises questions about the impact of the new lymphodepletion regimen and the strength of the response tail despite several cases lasting beyond two years. In addition, the company still faces meaningful regulatory risk from pending FDA and EMA approvals and competitive pressure from approved melanoma therapies and emerging CAR-T approaches in solid tumors, which could limit commercial success.

Iovance Biotherapeutics (IOVA) has been analyzed by 10 analysts, with a consensus rating of Buy. 40% of analysts recommend a Strong Buy, 40% recommend Buy, 20% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Iovance Biotherapeutics and is not a guaranteed prediction by Public.com or investment advice.

Iovance Biotherapeutics (IOVA) Analyst Forecast & Price Prediction

Get the latest Iovance Biotherapeutics (IOVA) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Iovance Biotherapeutics (IOVA)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Iovance Biotherapeutics (IOVA) Forecast

Analysts have given Iovance Biotherapeutics (IOVA) a Buy based on their latest research and market trends.

According to 10 analysts, Iovance Biotherapeutics (IOVA) has a Buy consensus rating as of Nov 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $13.80, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $13.80, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Iovance Biotherapeutics (IOVA)


Iovance Biotherapeutics (IOVA) Analyst Forecast & Price Prediction

Get the latest Iovance Biotherapeutics (IOVA) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Iovance Biotherapeutics (IOVA)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover IOVA stock data and trends